Handa Pharmaceuticals Inc banner
H

Handa Pharmaceuticals Inc
TPEX:6620

Watchlist Manager
Handa Pharmaceuticals Inc
TPEX:6620
Watchlist
Price: 127.5 TWD 2% Market Closed
Market Cap: NT$21.7B

Wall St Price Targets

Price Forecast
Based on 5 analysts

-34% Downside
from NT$127.5 today

Handa Pharmaceuticals Inc (6620)’s 12-month stock price forecast through October 2027 has a consensus target of NT$84.66, implying 34% downside. The forecast is based on price targets from 5 Wall Street analysts.

Analyst Rating
No ratings yet

No rating

We don't have analyst ratings for Handa Pharmaceuticals Inc yet.

Handa Pharmaceuticals Inc Competitors:
Price Targets

Financial forecasts

Past growth per year

Average annual growth cannot be calculated for these periods.

Explore analyst estimates, growth and forecast ranges.

Reported Lowest–highest estimate

Value YoY Lowest–highest Analysts
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is Handa Pharmaceuticals Inc's stock price target?
Price Target
84.66 TWD

According to Wall Street analysts, the average 1-year price target for Handa Pharmaceuticals Inc is 84.66 TWD with a low forecast of 83.83 TWD and a high forecast of 87.15 TWD.

What is the Revenue forecast for Handa Pharmaceuticals Inc?
Projected CAGR
34%

The compound annual growth rate for Revenue over the next 2 years is 34%.

What is the Gross Profit forecast for Handa Pharmaceuticals Inc?
Projected CAGR
41%

The compound annual growth rate for Gross Profit over the next 2 years is 41%.

What is the Operating Income forecast for Handa Pharmaceuticals Inc?
Projected CAGR
59%

The compound annual growth rate for Operating Income over the next 2 years is 59%.

What is the Pre-Tax Income forecast for Handa Pharmaceuticals Inc?
Projected CAGR
62%

The compound annual growth rate for Pre-Tax Income over the next 2 years is 62%.

What is the Net Income forecast for Handa Pharmaceuticals Inc?
Projected CAGR
56%

The compound annual growth rate for Net Income over the next 2 years is 56%.

Back to Top